Anti-HER2/neu CE/IVD immunohistochemistry (IHC) reagents are essential diagnostic tools for assessing HER2 protein overexpression in formalin-fixed, paraffin-embedded (FFPE) tissues.

HER2 (ERBB2) is a transmembrane tyrosine kinase receptor whose amplification or overexpression drives tumor aggressiveness in a significant proportion of breast carcinomas and selected gynecologic malignancies, particularly uterine serous carcinoma. Accurate HER2 IHC interpretation directly influences diagnostic classification, therapeutic decision-making, and patient prognosis in routine pathology practice.

These CE-marked reagents are optimized for consistent membrane staining quality, enabling pathologists to apply standardized scoring systems and maintain diagnostic concordance with in-situ hybridization (ISH) assays.

Diagnostic Utility in Breast Pathology

HER2 IHC is a cornerstone biomarker in breast cancer diagnostics. Anti-HER2/neu CE/IVD reagents support:

• Primary evaluation of HER2 status in invasive breast carcinoma using the internationally adopted 0/1+/2+/3+ scoring algorithm.
• Identification of HER2-positive tumors eligible for HER2-targeted therapies such as monoclonal antibodies, antibody–drug conjugates, and kinase inhibitors.
• Differentiation of true membranous overexpression from non-specific cytoplasmic staining through optimized antibody titration and validated protocols.
• Reflex testing workflows, where equivocal (2+) IHC results trigger confirmatory ISH to evaluate gene amplification.
• Quality assurance and inter-laboratory reproducibility, supported by standardized CE/IVD validation and QC-compatible staining performance.

HER2 IHC remains the first-line screening modality because of its rapid turnaround time, robust morphology-based interpretation, and strong clinicopathologic correlation with tumor behavior.

Diagnostic Utility in Gynecological Pathology

Although HER2 testing is well established in breast pathology, it is increasingly recognized as diagnostically valuable in select gynecologic tumors.

Uterine Serous Carcinoma (USC) & Carcinosarcoma

Anti-HER2/neu IHC helps pathologists:

• Identify HER2-overexpressing USC, which represents a clinically significant subset.
• Guide eligibility for HER2-directed therapy, now incorporated into treatment paradigms for HER2-positive USC.
• Improve diagnostic accuracy in cases with ambiguous morphology or mixed serous components.

Ovarian and Other Gynecologic Tumors

While HER2 positivity is less common, IHC supports:

• Refinement of tumor subclassification in mucinous and selected high-grade ovarian carcinoma variants.
• Correlation with molecular findings, aiding in biomarker-driven treatment strategies and enrollment in targeted therapy trials.

Diagnostic Advantages of Anti-HER2/neu CE/IVD Reagents

• Regulatory-grade analytical performance ensures high specificity for complete membranous staining patterns.
• Compatibility with automated platforms enhances standardization and reduces inter-operator variability.
• Reproducible interpretation aligned with international reporting guidelines.
• Robust performance on FFPE tissue, critical for routine clinical biopsies and surgical resections.
• Ideal for pathology laboratories focusing on breast and gynecologic oncologic diagnostics.